Abstract:
:Prothrombin time (PT) has been widely used for measuring anticoagulation intensity under rivaroxaban therapy, but precise information has not been well established yet. Consecutive 96 non-valvular atrial fibrillation (NVAF) under rivaroxaban between Jan/June, 2015 were recruited. Serum concentration (SC) and PT with 5 representative reagents available in Japan (Neoplastin Plus®, Thromborel S®, Thrombocheck PT®, Thrombocheck PT Plus®, and Recombiplastin®) at 2-4 hours after (peak) and before intake of rivaroxaban (trough) were measured at outpatient clinic in the cardiovascular institute (CVI ARO study 1). Nonlinear mixed-effects modelling was used to model the population pharmacokinetics and pharmacodynamics of rivaroxaban. An oral one-compartment model was employed to describe the population pharmacokinetics of rivaroxaban. The pharmacokinetics of rivaroxaban were affected by creatinine clearance, alanine aminotransferase, and use of CYP3A4 or P-gp inhibitors. PTs with 5 reagents were predicted by pharmacodinamic models with SC, hematocrit, serum albumin, and age, with medium predicting ability (highest/lowest R2 = 0.746/0.658 in Recombiplastin/Thromborel S, respectively). This population analysis in NVAF patients under rivaroxaban therapy demonstrated that pharmacokinetics of rivaroxaban was described by an oral one-compartment model with expected covariates, and can be assessed by PT with available reagents in Japan with medium predicting ability.
journal_name
Drug Metab Pharmacokinetjournal_title
Drug metabolism and pharmacokineticsauthors
Suzuki S,Yamashita T,Kasai H,Otsuka T,Sagara Kdoi
10.1016/j.dmpk.2018.02.002subject
Has Abstractpub_date
2018-08-01 00:00:00pages
188-193issue
4eissn
1347-4367issn
1880-0920pii
S1347-4367(17)30220-3journal_volume
33pub_type
杂志文章abstract::Forty-eight single nucleotide variations, including 27 novel ones, were found in the 5'- regulatory region, all of the exons and their surrounding introns of CYP2C19 in 253 Japanese subjects (134 diabetic patients and 119 healthy volunteers). Identified novel variations were as follows: -2772G>A, 2767_-2760delGGTGAACA...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.20.300
更新日期:2005-08-01 00:00:00
abstract::Protein kinases are potential drug targets for the treatment of a variety of diseases, including cancer. In particular, specific tyrosine kinase inhibitors are rapidly being developed as new drugs for the inhibition of malignant cell growth and metastasis formation. Most of these newly developed tyrosine kinase inhibi...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章,评审
doi:10.2133/dmpk.25.72
更新日期:2010-01-01 00:00:00
abstract::Genetic factors have a significant impact on the PK variability of EFV, much higher than other non-genetic factors, such as demography. In this work we have performed a comprehensive PG analysis of genes encoding the major metabolizing enzymes and transporters of EFV, establishing a clear relationship between the PK p...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2016.06.001
更新日期:2016-10-01 00:00:00
abstract::Repeated pretreatment with the antimalarial drug artemisinin (QHS) could lead to reduced exposure to the parent drug, which is mainly mediated by auto-induction of CYP2B6 activity. CYP2B6 is most sensitive to the inductive effect of constitutive androstane receptor (CAR), which can be activated by QHS. CYP2B6 polymorp...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 临床试验,杂志文章
doi:10.1016/j.dmpk.2014.10.008
更新日期:2015-02-01 00:00:00
abstract::UDP-glucuronosyltransferases (UGTs) are glycoproteins in endoplasmic reticulum membranes. UGT2B7 is an important UGT isoenzyme expressed in human liver and glucuronidates various endogenous and exogenous substances. Although this enzyme has three potential N-glycosylation sites (asparagine at positions 67, 68 and 315)...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.dmpk-11-rg-135
更新日期:2012-01-01 00:00:00
abstract::The aim of this study was to investigate the impact of genetic polymorphisms in the metabolic and cellular transport pathway of methotrexate (MTX) on the clinical outcome of MTX monotherapy in Japanese rheumatoid arthritis (RA) patients. Fifty-five patients were treated with MTX monotherapy at a dose of 4-10 mg/week. ...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.dmpk-11-rg-066
更新日期:2012-01-01 00:00:00
abstract::In vivo percutaneous absorption of emedastine difumarate was investigated in rats and compared with rat skin in vitro. Since emedastine entering the systemic circulation is mostly excreted in bile, we first came up with the method of collecting bile with a minimal skin incision. In vivo skin permeation of the drug was...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.20.331
更新日期:2005-10-01 00:00:00
abstract::Morphine is one of the strongest analgesics and is commonly used for the treatment of chronic pain. The pharmacokinetic properties of morphine are, in part, modulated by P-glycoprotein (P-gp). We previously reported that intestinal P-gp expression levels are influenced via the activation of inducible nitric oxide synt...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.dmpk-11-rg-051
更新日期:2011-01-01 00:00:00
abstract::Hypoglycemia is one of the serious adverse effects induced by cibenzoline (CBZ), an antiarrhythmic agent. In order to clarify the pharmacodynamics of CBZ-induced hypoglycemia, CBZ was administered intravenously to conscious rats at a dose of 5, 10 or 20 mg/kg and serum samples were collected periodically to determine ...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.DMPK-10-RG-127
更新日期:2011-06-01 00:00:00
abstract::The hepatic uptake transporter organic anion transporting polypeptide (OATP) 1B1 is inhibited by some uremic toxins; however, direct inhibition can only partially explain the delayed systemic elimination of substrate drugs in renal failure patients. This study aimed to examine the long-lasting inhibition of OATP1B1 by...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2020.09.001
更新日期:2020-12-01 00:00:00
abstract::Analysis of mRNAs from liver biopsy samples of patients with chronic hepatitis C revealed that the levels of nuclear receptor expression were correlated with those of drug-metabolizing enzymes and transporters in relation to the development of fibrosis. Overall, the median mRNA level was largely dependent on fibrosis ...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.dmpk-11-rg-077
更新日期:2012-01-01 00:00:00
abstract::MCT1(SLC16A1) is the first member of the monocarboxylate transporter (MCT) and its family is involved in the transportation of metabolically important monocarboxylates such as lactate, pyruvate, acetate and ketone bodies. This study identifies genetic variations in SLC16A1 in the ethnic Chinese group of the Singaporea...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.24.469
更新日期:2009-01-01 00:00:00
abstract::DDI could be caused by the inhibition of OATP-mediated hepatic uptakes. The aim of this study is to set the risk criteria for the compounds that would cause DDI via OATP inhibition at the drug discovery stage. The IC50 values of OATP inhibitors for human OATP-mediated atorvastatin uptake were evaluated in the expressi...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2016.05.003
更新日期:2016-10-01 00:00:00
abstract::The objective of this work was to develop a population pharmacokinetic model to assess the influence of subject covariates on the pharmacokinetics of valsartan in children. Data were collected from a single dose study in 26 hypertensive children ages 1 to 16 years. Subjects received 2 mg/kg valsartan suspension up to ...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章,多中心研究
doi:10.2133/dmpk.24.145
更新日期:2009-01-01 00:00:00
abstract::The object of this analysis was to develop a population pharmacokinetic model of micafungin, a new anti-fungal agent of the echinocandin class, to optimize dosing in Japanese patients with fungal infections. Population pharmacokinetics parameters were determined using NONMEM based on pharmacokinetic data from 198 subj...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 临床试验,杂志文章
doi:10.2133/dmpk.21.324
更新日期:2006-08-01 00:00:00
abstract::UDP-glucuronosyltransferases (UGTs) catalyze the glucuronidation of a wide variety of xeno/endobiotics. Previous studies have reported that human UGT enzymes are phosphorylated and that treatment of cells with protein kinase C (PKC) inhibitors results in decreased UGT activities without affecting the UGT protein level...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.DMPK-10-RG-121
更新日期:2011-06-01 00:00:00
abstract::Polymorphic human flavin-containing monooxygenase (FMO) 3 is an important drug-metabolizing enzyme for nitrogen- or sulfur-containing compounds. Cynomolgus macaques, a non-human primate species widely used in drug metabolism studies, have corresponding FMO3 molecular and enzymatic similarities to humans; however, gene...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2018.09.001
更新日期:2019-02-01 00:00:00
abstract::Over the past few decades, monoclonal antibodies (mAbs) have become one of the most important and fastest growing classes of therapeutic molecules, with applications in a wide variety of disease areas. As such, understanding of the determinants of mAb pharmacokinetic (PK) processes (absorption, distribution, metabolis...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章,评审
doi:10.1016/j.dmpk.2018.11.002
更新日期:2019-02-01 00:00:00
abstract::Pairs of forward and reverse primers and TaqMan probes specific to each human nuclear receptor were prepared. Analysis of the mRNA expression level of each target of 43 nuclear receptors in total RNA from single and pooled specimens of various human organs (liver, kidney, adrenal gland, lung, heart, brain, cerebellum,...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.19.135
更新日期:2004-04-01 00:00:00
abstract::The ATP-binding cassette transporter, ABCG2, which is expressed at high levels in the intestine and liver, functions as an efflux transporter for many drugs, including clinically used anticancer agents such as topotecan and the active metabolite of irinotecan (SN-38). In this study, to elucidate the linkage disequilib...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.21.109
更新日期:2006-04-01 00:00:00
abstract::Tralokinumab is a human monoclonal antibody in clinical development for asthma and atopic dermatitis that specifically neutralizes interleukin-13. This phase I, single-blind, randomized, placebo-controlled, single ascending-dose study assessed the safety, tolerability, pharmacokinetics (PK), and immunogenicity of subc...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章,随机对照试验
doi:10.1016/j.dmpk.2017.12.001
更新日期:2018-06-01 00:00:00
abstract::Specific antibody production is an important issue in crossover pharmacokinetic (PK) studies of protein-based formulations. We recently reported that intravenous co-administration of tacrolimus with multiple human interferon-alpha (h-IFN) administrations successfully suppressed the production of anti-h-IFN antibodies ...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.25.149
更新日期:2010-01-01 00:00:00
abstract::In this study, we aimed to understand the gap in coverage of pharmacogenomic (PGx) biomarkers between Japan and the US. PGx biomarkers (1) in the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines; (2) that are CPIC level A or B; or (3) have US Food and Drug Administration (FDA)-approved drug labels...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2018.08.006
更新日期:2018-12-01 00:00:00
abstract::Cytochrome P450 2A6 (CYP2A6) is an enzyme involved in the metabolism of tobacco carcinogens, which are important risk factors in lung cancer. We and others have previously reported that CYP2A6*4, a whole-gene deletion polymorphism, is associated with lower risk of lung cancer than the wild-type allele. However, the ge...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2015.04.002
更新日期:2015-08-01 00:00:00
abstract::New SRM (selected reaction monitoring) data dependent exclusion (MS)(n) measurement makes it possible to obtain MS(3) fragmentation data for all MS(2) fragments, useful for structural determination of drug metabolites using ESI ion trap. MS(2) fragments are produced by cleavage of all protonated molecules at the lone ...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.18.390
更新日期:2003-01-01 00:00:00
abstract::Microdose (MD) clinical trials have been introduced to obtain human pharmacokinetic data early in drug development. Here we assessed the cost-effectiveness of microdose integrated drug development in a hypothetical model, as there was no such quantitative research that weighed the additional effectiveness against the ...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.dmpk-12-rg-044
更新日期:2013-01-01 00:00:00
abstract::Most of cytochrome P450 (CYP) expressions are regulated by nuclear receptors. The regulation pathways of transcription are activated by binding of the ligand to the receptor. Many combination of CYPs and nuclear receptors in transcriptional regulation have been reported. However, we have reported that the combination ...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2018.04.002
更新日期:2018-08-01 00:00:00
abstract::Tacrolimus is a widely used immunosuppressant after organ transplantation. The narrow therapeutic window and individual variability in tacrolimus pharmacokinetics make management of this agent a great challenge. This study was undertaken to determine the association of clinical markers, cytochrome P450, family 3, subf...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.dmpk-13-rg-095
更新日期:2014-01-01 00:00:00
abstract::Oligopeptide transporter PEPT1 is thought to be involved in the intestinal absorption and renal reabsorption of peptides and therapeutic agents. The driving force of PEPT1 is H+ gradient, a part of which is supplied by Na+/H+ exchanger (NHE) expressed on the apical surface of the epithelium although molecular identifi...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.20.443
更新日期:2005-12-01 00:00:00
abstract::This exploratory retrospective study examined the effects of polymorphisms in transporter genes related to irinotecan pharmacokinetics and those in genes related to irinotecan pharmacodynamics on the efficacy of first-line combination chemotherapy with irinotecan, 5-fluorouracil, and folinic acid (leucovorin) (FOLFIRI...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.dmpk-11-rg-128
更新日期:2012-01-01 00:00:00